| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.026 | 0.9 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | 0.029 | 0.9 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.9 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |